Medical Devices industry cross border deals total $2.89bn globally in March 2021

Total medical devices industry cross border deals worth $2.89bn were announced globally for March 2021, with the $1.07bn asset transaction with Lumenis being the sector’s biggest investment, according to GlobalData’s deals database.

The value marked an increase of 381.8% over the previous month of $599.82m and a rise of 2.5% when compared with the last 12-month average of $2.82bn.

In terms of number of cross border deals, the sector saw a rise of 25.64% with 49 deals in March 2021 when compared to the last 12-month average of 39 deals.

In value terms, Middle East and Africa led the activity with cross border deals worth $1.21bn in March 2021.

Medical Devices industry cross border deals in March 2021: Top deals

The top five cross border deals accounted for 60.9% of the overall value during March 2021.

The combined value of the top five cross border deals stood at $1.76bn, against the overall value of $2.89bn recorded for the month.

The top five medical devices industry cross border deals of March 2021 tracked by GlobalData were:

1) Boston Scientific’s $1.07bn asset transaction with Lumenis

2) The $240m acquisition of Alydia Health by Organon &

3) L Catterton Partners’ $181.4m private equity deal with PHC

4) The $159m acquisition deal of Diagenode by Hologic

5) SeaSpine’s acquisition deal with 7D Surgical for $110m.